Aquestive Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M | $45.8M | $52.6M | $67.4M |
| Cost of Revenue | $18.6M | $17.9M | $20.8M | $19.4M | — | $13.0M | $20.4M | — |
| Gross Profit | $26.0M | $39.7M | $29.8M | $28.3M | — | $32.9M | $32.2M | — |
| Gross Margin | 58.3% | 69.0% | 58.8% | 59.3% | — | 71.7% | 61.3% | — |
| Operating Expenses | ||||||||
| Research & Development | $17.2M | $20.3M | $13.1M | $17.5M | $17.0M | $19.9M | $20.6M | $23.1M |
| SG&A Expense | $79.8M | $50.2M | $31.8M | $52.9M | $53.5M | $55.9M | $64.3M | $72.3M |
| Operating Income | $-71.1M | $-30.8M | $-15.1M | $-42.1M | $-34.7M | $-42.9M | $-52.7M | $-48.9M |
| Operating Margin | -159.5% | -53.5% | -29.9% | -88.2% | -68.2% | -93.6% | -100.1% | -72.6% |
| Interest Expense | — | — | $6.3M | $6.6M | $10.0M | $11.1M | $9.3M | $7.7M |
| Pretax Income | $-83.8M | $-44.2M | $-7.6M | $-54.4M | $-70.5M | $-55.8M | $-66.2M | $-61.4M |
| Income Tax Expense | $0 | $-14.0K | $245.0K | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-83.8M | $-44.1M | $-7.9M | $-54.4M | $-70.5M | $-55.8M | $-66.2M | $-61.4M |
| Net Margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% |
| EPS (Basic) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | $-2.61 | $-2.96 |
| EPS (Diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | $-2.61 | $-2.96 |
| Shares Outstanding (Basic) | 106.9M | 86.7M | 61.3M | 48.7M | 38.1M | 33.7M | 33.6M | 25.0M |
| Shares Outstanding (Diluted) | 106.9M | 86.7M | 61.3M | 48.7M | 38.1M | 33.7M | 33.6M | 25.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |